Application of saponin in preparation of antihypertensive products
By using saponin as the active ingredient of blood pressure-lowering drugs, the problem of major side effects of existing hypertensive drugs has been solved, and the effect of significantly lowering blood pressure and improving cardiovascular health has been achieved, especially vascular endothelial protection and lipid metabolism abnormalities. Reduce the risk of atherosclerosis.
Patent Information
- Application Number
- CN202411217304.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-12-06
AI Technical Summary
Although existing drugs for treating hypertension can significantly lower blood pressure, they have great side effects and have limited protection against vascular endothelial, resulting in an urgent need to find effective antihypertensive drugs with small side effects.
Saponin is used as an active ingredient for blood pressure-lowering products, and is prepared as a drug or health food by reducing the thickness of the middle layer of the vascular endometrium, improving abnormal lipid metabolism, and reducing the risks of atherosclerosis and coronary heart disease.
Saponin significantly lowers blood pressure, reduces total cholesterol and low-density lipoprotein levels, increases high-density lipoprotein, improves angiosclerosis and myocardial hypertrophy in hypertensive mice, reduces the risk of atherosclerosis and coronary heart disease, and the effect is dose-dependent sex.
Smart Images

Figure CN119074748A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of saponin in the preparation of blood pressure lowering products. Background Art
[0002] Hypertension refers to the pressure on the blood vessel wall caused by blood flowing in the blood vessels that is higher than normal. It is one of the most common cardiovascular diseases and an important risk factor for diseases such as stroke, coronary heart disease, and heart failure. In the absence of antihypertensive drugs, hypertension can be diagnosed when three blood pressure values measured on different days are higher than normal, that is, systolic blood pressure ≥140mmHg, and (or) diastolic blood pressure ≥90mmHg. Hypertension is currently the most common disease with a very high incidence and growth rate, which seriously endangers human health. Nowadays, people are paying more and more attention to the treatment of hypertension.
[0003] However, the existing drugs for treating hypertension are mainly Western medicines. Although they have significant antihypertensive effects, they also have great side effects and limited protective effects on the vascular endothelium of hypertensive patients. Long-term use of these synthetic drugs will produce some adverse reactions, such as dry cough, taste disorders, rashes and allergic reactions. Therefore, it is particularly necessary to find drugs with significant antihypertensive effects, few side effects and protection of the vascular endothelium of hypertensive patients. Summary of the invention
[0004] The purpose of the present invention is to provide the use of saponin in the preparation of antihypertensive products, enrich the types of antihypertensive drugs, have significant antihypertensive effects, and have few side effects.
[0005] The present invention provides application of saponin in preparing a blood pressure lowering product.
[0006] Preferably, the blood pressure lowering product includes a product for preventing and / or treating cardiovascular diseases.
[0007] Preferably, the product for preventing and / or treating cardiovascular diseases includes products for preventing and / or treating one or more of hypertension, hyperlipidemia, vascular sclerosis, myocardial hypertrophy, atherosclerosis and coronary heart disease.
[0008] Preferably, the blood pressure lowering product includes a product that prevents vascular remodeling, thereby lowering blood pressure.
[0009] Preferably, the prevention of vascular remodeling comprises reducing the thickness of the vascular intima-media layer.
[0010] Preferably, the blood pressure lowering product includes a product that improves abnormal lipid metabolism, thereby lowering blood pressure.
[0011] Preferably, the lipid metabolism index includes one or more of total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein and arteriosclerosis index.
[0012] Preferably, the blood pressure lowering product includes a product that improves the oxidative stress response of hepatocytes, thereby lowering blood pressure.
[0013] The present invention also provides a blood pressure lowering product, wherein the medicinal effect or effective component of the blood pressure lowering product is saponin; the product is a medicine or a health food.
[0014] Preferably, the product is formulated as a single-use dosage form with 77-308 mg of saponin per dose.
[0015] Beneficial effects:
[0016] The present invention provides the use of saponin in the preparation of a blood pressure-lowering product. The present invention finds that saponin has a blood pressure-lowering effect, can reduce the thickness of the intima-media layer of blood vessels, prevent aortic remodeling, reduce total cholesterol and low-density lipoprotein levels, increase high-density lipoprotein levels, regulate abnormal lipid metabolism in hypertension, improve vascular sclerosis and myocardial hypertrophy in hypertensive mice, and reduce the risk of atherosclerosis and coronary heart disease in a dose-dependent manner. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.
[0018] Figure 1 The systolic blood pressure (SBP) test results of mice in different treatment groups;
[0019] Figure 2 Diastolic blood pressure (DBP) test results of mice in different treatment groups;
[0020] Figure 3 The weight test results of mice in different treatment groups after the last administration;
[0021] Figure 4 The results of body weight test of mice in different treatment groups during drug administration;
[0022] in, Figures 1 to 4 △ in the middle indicates P < 0.05 compared with the control group, and * indicates P < 0.05 compared with the model group;
[0023] Figure 5 Results of serum TG, T-CHO, HDL-CL and DL-C in mice in different treatment groups;
[0024] Figure 6 The results of serum lipid index test of mice in different treatment groups;
[0025] Figure 7 The results of serum ALT, AST, and AKP in mice in different treatment groups;
[0026] Figure 8 The results of HE staining of kidneys of mice in different treatment groups (4X); the red arrows indicate renal tissue necrosis; the yellow arrows indicate inflammatory cell infiltration;
[0027] Fig. 9 The results of serum BUN test of mice in different treatment groups;
[0028] Fig.10 Serum CER test results of mice in different treatment groups;
[0029] Fig.11 HE staining results of aorta vessels of mice in different treatment groups (10X);
[0030] Fig.12 The results of the aorta intima-media thickness test of mice in different treatment groups;
[0031] in, Figures 5 to 7 , Figures 9-10 and Fig.12 Different letters indicate significant differences. DETAILED DESCRIPTION
[0032] The present invention provides the use of saponin in the preparation of a blood pressure lowering product. The purity of the saponin of the present invention is preferably greater than 98%. The present invention has no strict requirements on the source of the saponin, which can be purchased directly or prepared by itself. The product of the present invention is preferably a medicine or a health food. The CAS number of the saponin used in the embodiment of the present invention is 20310-89-8.
[0033] In the present invention, the blood pressure lowering product preferably includes a product for preventing and / or treating cardiovascular diseases; the product for preventing and / or treating cardiovascular diseases includes a product for preventing and / or treating one or more of hypertension, hyperlipidemia, vascular sclerosis, myocardial hypertrophy, atherosclerosis and coronary heart disease, and is further preferably a product for preventing and / or treating hypertension. The present invention uses saponin as an active ingredient, which can improve vascular sclerosis and myocardial hypertrophy in hypertensive mice, and reduce the risk of atherosclerosis and coronary heart disease in a dose-dependent manner.
[0034] In the present invention, the blood pressure lowering product preferably includes a product that prevents vascular remodeling and lowers blood pressure. The prevention of vascular remodeling in the present invention preferably includes reducing the thickness of the vascular intima-media layer. The present invention uses saponin as an active ingredient, which can reduce the thickness of the vascular intima-media layer induced by L-NAME, prevent aortic remodeling, and has a blood pressure lowering effect.
[0035] In the present invention, the blood pressure lowering product preferably includes a product that improves lipid metabolism abnormalities and lowers blood pressure. The lipid metabolism index of the present invention preferably includes one or more of total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein and arteriosclerosis index, and is further preferably total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein and arteriosclerosis index. The present invention uses saponin as an active ingredient, which can reduce the total cholesterol, triglycerides, and low-density lipoprotein content induced by L-NAME, increase the content of high-density lipoprotein, and significantly reduce the four blood lipid indexes, thereby improving lipid metabolism abnormalities and having a blood pressure lowering effect.
[0036] In the present invention, the blood pressure lowering product preferably includes a product that improves the oxidative stress response of liver cells and lowers blood pressure. The present invention uses saponin as an active ingredient, which can significantly improve the oxidative stress response of liver cells in L-NAME-induced hypertensive mice and has a blood pressure lowering effect.
[0037] The present invention also provides a blood pressure lowering product, wherein the drug effect or effective ingredient of the blood pressure lowering product is saponin; the product is a medicine or a health food. The product of the present invention is formulated as a dosage form for one-time use with 77 to 308 mg of saponin / dose, and more preferably, 154 mg of saponin / dose is formulated as a dosage form for one-time use. The dosage of saponin in the product of the present invention is preferably a daily dosage for a person weighing 70 kg.
[0038] In order to further illustrate the present invention, the application of saponin provided by the present invention in the preparation of blood pressure lowering products is described in detail below in combination with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.
[0039] Data analysis of the present invention was performed using GraphPadprism 6, and statistical analysis was performed using one-way ANOVA and Tukey post hoc test. p<0.05 was considered statistically significant. Images were digitally recorded and analyzed using NIU image analysis software and ImageJ software, and aortic media thickness was calculated. All data are expressed as mean ± standard error mean (Mean ± SEM)
[0040] Example 1
[0041] 1. Experimental reagents and instruments
[0042] Reagents: NG-nitro-L-arginine methyl ester hydrochloride (L-NAME, ST1555), hematoxylin-eosin stain (C0105M), hydrochloric acid ethanol slow differentiation solution (C0165M), BCA protein concentration determination kit (P0010S) were purchased from Shanghai Biyuntian Biotechnology Co., Ltd.; total cholesterol (T-CHO, A111-1-1), triglycerides (TG, A110-1-4), low-density lipoprotein cholesterol The test kits for low-density lipoprotein cholesterol (LDL-C, A113-1-1), high-density lipoprotein cholesterol (HDL-C, A112-1-1), aspartate aminotransferase (AST, C010-2-1), alanine aminotransferase (ALT, C009-2-1), alkaline phosphatase (AKP, A059-2-2), blood urea nitrogen (BUN, C013-2-1), and creatinine (CRE, C011-2-1) were purchased from Nanjing Jiancheng Bioengineering Institute;
[0043] Instruments: intelligent non-invasive sphygmomanometer for mice and rats (BP-2010A, Ruanlong, Beijing), multifunctional live cell imaging microplate reader (Spark cyto 400, Tecan, Austria), UV-visible spectrophotometer (L5S, Instrument and Electrical Analysis, Shanghai), inverted fluorescence microscope (DS-Ri2, Nikon Eclipse, Japan), low-temperature high-speed centrifuge (Centrifuge5424R, Eppendorf, Germany), cryostat (CM 1860UV, Leica, Germany), water purifier (Millipore-QIntegral 3, Merk, Germany), handheld tissue grinder (MY-20, Jingxin, Shanghai).
[0044] 2. Establishment of Mouse Hypertension Model and Grouping and Drug Administration
[0045] (1) Male Kunming (KM) mice, weighing 18±2g, were adaptively fed for one week and randomly divided into a control group and a modeling group. The control group drank distilled water, and the modeling group added 2g / LNG-nitro-L-arginine methyl ester (L-NAME) to drinking water (distilled water). All mice were allowed to eat freely, and blood pressure and body weight were measured at fixed time points using the tail cuff method once a week to monitor diet and drinking water for 4 consecutive weeks. After 4 weeks, the systolic blood pressure (SBP) of the modeling group mice was greater than 140mmHg, indicating that they were hypertensive mice, and the modeling was successful.
[0046] (2) The hypertensive mice in the modeling group were randomly divided into a model group and a drug-treated group, and the drugs were administered by gavage according to Table 1 below; the control group was given distilled water, and the mice in each treatment group were given the drug continuously for 8 weeks.
[0047] Table 1 Drug administration method for mice in each treatment group
[0048]
[0049]
[0050] Test Example 1
[0051] 1. General
[0052] During the administration period of Example 1, there was no significant difference in the diet and water intake of mice in each treatment group.
[0053] 2. Blood pressure test
[0054] Blood pressure was measured using the tail cuff method. All mice were trained in a blood pressure analyzer for one week before modeling and administration to adapt the experimental mice to the measurement equipment and avoid blood pressure measurement errors caused by subsequent experimental stress. Example 1: Mice were fixed 1 hour after each administration, and systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured after preheating at 37°C for 10 minutes. Each mouse was measured 5 times in a row, once a week. The results are shown in the figure. Figure 1 and Figure 2 shown.
[0055] according to Figure 1 and Figure 2 It can be seen that the systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the mice in the model group were significantly higher than those in the control group. Compared with the model group, the SBP was significantly reduced after 1 week of administration of captopril (positive control) (P < 0.05), and the DBP was significantly reduced after 3 weeks of administration (P < 0.05); the SBP of the high-dose group was significantly reduced after 3 weeks of ZC administration (P < 0.05) ( Figure 1 ), and DBP in the high-dose group decreased significantly after 6 weeks of administration (P<0.05) ( Figure 2 ), there was no significant difference in SBP and DBP between the medium and low dose groups (P>0.05). This shows that ZC has a hypotensive effect, which is proportional to the dose.
[0056] 3. Weight test
[0057] Example 1: Body weight was measured at a fixed time and place after administration, once a week for 8 consecutive weeks. Figure 3 and Figure 4 shown.
[0058] according to Figure 3 and Figure 4 It can be seen that long-term induction of L-NAME caused a significant weight loss in mice, and the final body weight after 8 weeks of ZC administration was significantly higher than that of the model group ( Figure 3 ); During the drug administration period, the body weight of the model group was lower than that of the control group, and the area under the body weight curve (AUC) was significantly reduced; compared with the model group, the AUC of the captopril group was slightly increased, but not statistically significant; the AUC of the low-dose ZC group was not statistically significant, and the AUC of the medium- and high-dose ZC groups was significantly increased ( Figure 4). The results showed that ZC could improve the weight loss of L-NAME-induced hypertensive mice.
[0059] 4. Visceral system number
[0060] Example 1 Two hours after the last administration, the mice were killed, and the heart, kidney, liver, spleen, and lung were collected and weighed. The organ system weight (organ weight / body weight) of each organ of the mice in each treatment group was calculated. The results are shown in Table 2.
[0061] Table 2 Viscera number of mice in different treatment groups
[0062]
[0063]
[0064] Note: Different letters in each row indicate that the mean values are significantly different, P < 0.05.
[0065] According to Table 2, the number of cardiac organs in the L-NAME-induced group of mice was significantly higher than that in the other groups, which was related to myocardial hypertrophy caused by hypertension; no significant difference was observed in the liver, kidney, lung, and spleen; after 8 weeks of administration, captopril could significantly reduce the increase in heart weight caused by L-NAME and reduce the number of organ systems; the medium and high dose groups of ZC could significantly reduce the increase in heart weight caused by L-NAME and reduce the number of organ systems, which was equivalent to the positive control effect and proportional to the dose; no significant difference was observed in the liver, kidney, lung, and spleen. The results showed that ZC could inhibit myocardial hypertrophy caused by L-NAME and had a protective effect on the heart.
[0066] 5. Serum biochemical index detection
[0067] Example 1 Two hours after the last administration, mice were killed, and blood samples were collected and coagulated at room temperature for 2 hours. The blood samples were centrifuged at 4°C, 3500 rpm / min for 10 minutes, and the serum was separated and stored at 80°C for the detection of serum biochemical indicators.
[0068] (1) Serum total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C) related to lipid metabolism
[0069] L-NAME-induced hypertensive mice are characterized by high levels of TC, LDL-C, VLDL-C, TG and low levels of HDL-C. Hypertension and hyperlipidemia are two related cardiovascular risk factors. Therefore, hypertension and dyslipidemia should be controlled to reduce cardiovascular harm.
[0070] This experiment detected the changes in serum TC, TG, HDL-C, LDL-C content and related blood lipid indexes related to lipid metabolism, studied the blood lipid levels of mice in each treatment group after 8 weeks of administration, and evaluated the damage of the samples to cardiovascular and cerebrovascular diseases such as atherosclerosis and coronary heart disease. The test results are as follows Figure 5 and Figure 6 As shown in the figure, HDL-C is negatively correlated with the occurrence of coronary heart disease, TG is closely related to the risk of atherosclerotic cardiovascular disease, the larger the value of the atherosclerosis index (AI), the more severe the degree of arteriosclerosis, and the higher the risk of cardiovascular and cerebrovascular diseases; serum LDL-C / HDL-C is an important risk factor for coronary heart disease, and TG / HDL-C is used to predict the risk of coronary heart disease; TC / HDL-C as a comprehensive blood lipid index can better express abnormal lipid metabolism.
[0071] according to Figure 5 It can be seen that compared with the control group, the TG, T-CHO, and LDL-C of the model group mice increased significantly, and HDL-C decreased significantly, showing obvious dyslipidemia. Compared with the model group, after 8 weeks of administration, the positive control captopril can significantly reduce the level of LDL-C, but has no effect on TG, T-CHO, and HDL-C; the high-dose ZC group can significantly reduce TC, and the medium and high-dose groups can significantly reduce the level of LDL-C and increase HDL-C in a dose-dependent manner, but has no effect on TG.
[0072] according to Figure 6 It can be seen that compared with the control group, the arteriosclerosis index (AI), LDL-C / HDL-C, TC / HDL-C, and TG / HDL-C indices of mice in the model group were significantly increased, indicating abnormal lipid metabolism, which leads to a higher risk of arteriosclerosis, coronary heart disease, and death; after 8 weeks of administration, the positive control captopril can significantly reduce the LDL-C / HDL-C index, and there is no difference in AI, TC / HDL-C and TG / HDL-C indices; ZC can significantly reduce AI, LDL-C / HDL-C and TG / HDL-C, TC / HDL-C indices, and is proportional to the dose.
[0073] In summary, Captopril can reduce LDL-C and LDL-C / HDL-C, thereby reducing the risk of coronary heart disease in hypertensive mice, but has no improvement on abnormal lipid metabolism; ZC can significantly reduce the four blood lipid indexes by reducing TC and LDL-C, increasing HDL-C, thereby improving abnormal lipid metabolism caused by hypertension and reducing the risk of cardiovascular diseases such as atherosclerosis and coronary heart disease.
[0074] (2) Serum ALT, AST, and AKP tests related to liver function
[0075] This experiment detected the serum ALT, AST, and AKP levels related to liver function. The results are as follows Figure 7 As shown. Figure 7 It can be seen that compared with the control group, the AST of the mice in the model group increased significantly, while ALT and AKP did not change significantly. The increase in serum AST content is related to mitochondrial damage of hepatocytes, indicating that continuous administration of L-NAME for 12 weeks can induce significant oxidative stress in mouse hepatocytes. Compared with the model group, after 8 weeks of administration, the positive control captopril had no effect on AST; the ZC group could significantly reduce the AST level in a dose-dependent manner. The results showed that captopril had no improvement on the oxidative stress of hepatocytes caused by L-NAME, and ZC could significantly improve the cellular oxidative stress response of the liver of L-NAME-induced hypertensive mice.
[0076] 6. Kidney tissue index detection
[0077] Example 1 Mice were killed 2 hours after the last administration, and blood samples were collected and coagulated at room temperature for 2 hours. Serum was separated by centrifugation at 4°C, 3500 rpm / min for 10 minutes, and serum was used for serum BUN and CER detection. Kidneys were collected and immersed in 10% neutral formalin for HE staining. The results are shown in Figures 8 to 10 shown.
[0078] according to Figures 8 to 10 It can be seen that after 12 weeks of L-NAME induction (4 weeks of modeling + 8 weeks of drug administration), the glomerular and tubular tissue structures of mice in the control group were normal, the morphological structure was intact, and no obvious pathological damage was observed; in the model group, partial renal tissue necrosis was observed, accompanied by inflammatory cell infiltration ( Figure 8 ), there was no significant difference in BUN and CRE among the groups ( Fig. 9 and Fig.10 ), indicating that L-NAME induced mild pathological damage to renal tissue after 12 weeks; a small amount of necrotic tissue and inflammatory cell infiltration were observed in the captopril group; the necrotic tissue in the kidney of the ZC group was reduced, and no significant inflammatory cell infiltration was observed, which improved the inflammatory cell infiltration in the kidney of hypertensive mice in a dose-dependent manner.
[0079] 7. Detection of aortic vascular tissue indicators
[0080] Example 1 Two hours after the last administration, the mice were killed, and the thoracic aorta was carefully separated along the aortic arch, and the connective tissue was removed. Do not pull to cause artificial vascular damage. The thoracic aorta was immersed in 10% neutral formalin and stained with HE. The results are as follows Figure 11-12 shown.
[0081] according to Fig.11 and Fig.12It can be seen that the thoracic aorta intima of the control group was relatively smooth, the endothelial cells were intact, and no obvious abnormalities were observed; the thoracic aorta wall of the model group was of varying thickness, the intima was relatively rough, the proliferation was serious, and the thickness of the intima-media layer was significantly increased, indicating thoracic aorta vascular remodeling; the intima-media thickness of the captopril group was significantly reduced, which significantly improved the thoracic aorta vascular remodeling; the intima-media thickness of the ZC high-dose group was significantly reduced, which significantly improved the thoracic aorta vascular remodeling caused by hypertension.
[0082] Based on the above content, it can be seen that ZC has a hypotensive effect, can reduce the thickness of the vascular intima-media layer, and prevent aortic remodeling; reduce TC and LDL-C levels, increase HDL-C levels, regulate abnormal lipid metabolism in hypertension, improve vascular sclerosis and myocardial hypertrophy in hypertensive mice, and reduce the risk of atherosclerosis and coronary heart disease in a dose-dependent manner.
[0083] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. Application of saponin in the preparation of blood pressure lowering products.
2. The use according to claim 1, It is characterized in that The blood pressure lowering products include products for preventing and / or treating cardiovascular diseases.
3. The use according to claim 2, It is characterized in that The products for preventing and / or treating cardiovascular diseases include products for preventing and / or treating one or more of hypertension, hyperlipidemia, vascular sclerosis, myocardial hypertrophy, atherosclerosis and coronary heart disease.
4. The use according to claim 2, It is characterized in that The blood pressure lowering products include products that prevent vascular remodeling and thus lower blood pressure.
5. The use according to claim 4, It is characterized in that The prevention of vascular remodeling includes reducing the thickness of the vascular intima-media layer.
6. The use according to claim 2, It is characterized in that The blood pressure lowering products include products that improve abnormal lipid metabolism and thus lower blood pressure.
7. The use according to claim 6, It is characterized in that The lipid metabolism index includes one or more of total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein and arteriosclerosis index.
8. The use according to claim 2, It is characterized in that The blood pressure lowering product includes a product that improves the oxidative stress response of liver cells, thereby lowering blood pressure.
9. A blood pressure lowering product, It is characterized in that The efficacy or effective ingredient of the blood pressure lowering product is saponin; the product includes medicines or health foods.
10. The blood pressure lowering product according to claim 9, It is characterized in that The product is formulated as a single-use dosage form with 77 to 308 mg of saponin per dose.
Citation Information
Patent Citations
Preparation method of high-assay highland barley flavones and use thereof in preparing healthcare products
CN101361932A
Application of diosgenin in the preparation of drugs for inhibiting vascular calcification
CN109172590A
Application of wogonoside in preparation of products for reducing hypertension
CN116421610A
Separation and purification method and application of barley flavin monomer and saponins monomer
CN118084995A
Roller assembly for paper money counting
KR1020230057749A
